GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Samil Pharmaceutical Co 000520.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

7,270

-0.95%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩210.25bn

FY2016FY2025

Net income

−₩34.66bn

FY2016FY2025

Free cash flow

−₩6.95bn

FY2016FY2025

Shareholders' equity

₩133.26bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩210.25bn₩219.70bn₩196.35bn₩179.68bn₩134.25bn₩123.00bn₩121.11bn₩94.60bn₩92.04bn₩96.76bn
Gross profit₩77.12bn₩80.91bn₩74.07bn₩67.49bn₩48.99bn₩49.03bn₩46.72bn₩34.79bn₩40.91bn₩41.45bn
Research and development₩8.46bn₩6.51bn₩5.60bn₩2.91bn₩2.97bn₩3.01bn₩3.06bn₩2.18bn₩1.96bn₩1.25bn
Operating income−₩25.48bn₩113.0m₩6.47bn₩4.02bn₩399.7m₩6.54bn₩4.82bn−₩5.82bn₩1.31bn₩3.85bn
Net income−₩34.66bn−₩5.63bn₩1.66bn−₩28.3m−₩5.35bn₩1.34bn₩786.3m−₩8.56bn−₩1.27bn₩886.6m
Diluted earnings per share-5,658.46-918.84271.55-4.62-872.78218.83128.35-1,402.92-239.82167.88

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩371.60bn₩395.07bn₩370.68bn₩356.70bn₩226.40bn₩191.66bn₩183.87bn₩147.95bn₩135.48bn₩101.00bn
Total liabilities₩238.34bn₩218.95bn₩242.85bn₩230.88bn₩160.66bn₩128.11bn₩121.60bn₩91.87bn₩84.31bn₩48.12bn
Debt₩21.61bn₩84.39bn₩49.57bn₩71.92bn₩31.91bn₩20.00bn₩93.04bn₩66.71bn₩61.20bn₩30.20bn
Shareholders' equity₩133.26bn₩176.12bn₩127.83bn₩125.82bn₩65.75bn₩63.55bn₩62.27bn₩56.08bn₩51.17bn₩52.87bn
Shares outstanding6m6m6m6m6m6m6m6m5m5m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩568.2m₩2.59bn₩11.75bn₩4.15bn₩1.42bn₩7.77bn₩10.59bn−₩2.62bn₩3.79bn₩5.63bn
Capital spending−₩7.52bn−₩5.61bn−₩24.39bn−₩48.48bn−₩32.83bn−₩17.02bn−₩13.89bn−₩3.70bn−₩36.33bn−₩4.45bn
Free cash flow−₩6.95bn−₩3.02bn−₩12.65bn−₩44.33bn−₩31.41bn−₩9.24bn−₩3.30bn−₩6.33bn−₩32.54bn₩1.18bn
Dividends paid———−₩1.00bn−₩938.6m−₩918.9m−₩610.4m−₩765.5m−₩765.5m−₩1.02bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩50.60bn₩52.55bn₩53.00bn₩51.18bn₩53.79bn₩52.29bn₩57.79bn₩53.32bn
Gross profit₩18.93bn₩17.09bn₩19.45bn₩18.49bn₩20.72bn₩18.46bn₩20.53bn₩19.47bn
Operating income−₩6.27bn−₩8.38bn−₩8.57bn−₩5.43bn−₩3.11bn—−₩1.24bn−₩239.7m
Net income−₩7.69bn−₩10.83bn−₩11.16bn−₩7.93bn−₩6.50bn−₩9.08bn−₩3.56bn−₩676.2m
Diluted earnings per share-1,255.35-1,768.48-1,821.76-1,293.67-1,060.69-1,482.35-581.20-110.38
Cash from operations−₩3.48bn₩486.0m₩5.32bn₩2.79bn₩2.44bn−₩9.98bn₩2.43bn₩627.0m
Capital spending−₩596.0m−₩3.40bn−₩2.59bn−₩1.05bn−₩3.26bn−₩629.0m−₩2.11bn−₩1.84bn
Free cash flow−₩4.07bn−₩2.92bn₩2.73bn₩1.74bn−₩815.0m−₩10.61bn₩326.0m−₩1.21bn
Total assets₩374.73bn₩372.34bn₩371.60bn₩377.44bn₩375.58bn₩396.21bn₩395.07bn₩384.23bn
Debt₩51.14bn₩46.76bn₩21.61bn₩56.73bn₩58.69bn₩60.18bn₩84.39bn₩67.64bn
Shareholders' equity₩125.55bn₩128.56bn₩133.26bn₩143.09bn₩149.26bn₩166.15bn₩176.12bn₩174.65bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue5.4%11.3%9.1%
Net income970.1%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin36.8%37.2%37.4%38.5%
Operating margin-5.9%-1.8%-0.7%-0.1%
Net margin-9.4%-4.8%-4.0%-3.2%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-1.7-14.324.7-1858.1-9.647.182.0-7.3-17.124.1
Price to sales0.30.40.20.30.40.50.50.70.20.2

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 29 Dec 2021.

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Paid in the year72.72768.18268.18245.45565.88765.88787.84987.849
  • 2-for-1 split · 12 Apr 2021
  • 5-for-1 split · 24 Apr 2006
  • 1.054-for-1 split · 2 Jan 2001
  • 1.071-for-1 split · 4 Jan 2000
  • 1.021-for-1 split · 4 Jan 1999
  • 1.021-for-1 split · 3 Jan 1998

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.